Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study

Matsumoto, Kinnosuke; Yamamoto, Yuji; Shiroyama, Takayuki; Kuge, Tomoki; Mori, Masahide; Tamiya, Motohiro; Kinehara, Yuhei; Tamiya, Akihiro; Suzuki, Hidekazu; Tobita, Satoshi; Ueno, Kiyonobu; Niki, Toshie; Nagatomo, Izumi; Takeda, Yoshito; Kumanogoh, Atsushi

doi:https://doi.org/10.1007/s11523-024-01084-7

Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study

Matsumoto, Kinnosuke; Yamamoto, Yuji; Shiroyama, Takayuki et al.

Targeted Oncology, 2024

アクセス数:29件（2025-04-06 22:05 集計）

固定URL: https://hdl.handle.net/11094/98102

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
TargetedOncol_s11523-024-01084-7	pdf	なし	1.77 MB	27	2024.09.19

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study
著者	著者名 Matsumoto, Kinnosuke
	著者名 Yamamoto, Yuji
	NRID 1000060860062 1000060860062 researchmap permalink shiroyama_t shiroyama_t Scopus Author ID 36476578400 36476578400 著者名 Shiroyama, Takayuki
	著者名 Kuge, Tomoki
	著者名 Mori, Masahide
	著者名 Tamiya, Motohiro
	著者名 Kinehara, Yuhei
	著者名 Tamiya, Akihiro
	著者名 Suzuki, Hidekazu
	著者名 Tobita, Satoshi
	著者名 Ueno, Kiyonobu
	著者名 Niki, Toshie
	NRID 1000010570583 1000010570583 researchmap permalink saxon-w saxon-w Scopus Author ID 13404305500 13404305500 著者名 Nagatomo, Izumi
	NRID 1000040452388 1000040452388 researchmap permalink yoshi10 yoshi10 Scopus Author ID 7404001848 7404001848 著者名 Takeda, Yoshito
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 著者名 Kumanogoh, Atsushi
内容	The version of record of this article, first published in Targeted Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s11523-024-01084-7.
抄録	Background: Chemoimmunotherapy is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, data on clinical predictive factors remain scarce. Objective: We aim to identify clinical biomarkers in patients undergoing chemoimmunotherapy. Methods: This multicenter, real-world cohort study included chemonaive patients who underwent chemoimmunotherapy between December 2018 and May 2022. Multivariate analysis was used to determine associations between survival outcomes and patient background, including baseline neutrophil-to-lymphocyte ratio (NLR) and its dynamic change (ΔNLR). To further investigate the clinical significance of NLR, patients were classified based on their peripheral immune status, defined by a combination of NLR and ΔNLR. Results: The study included 280 patients with 30.1 months of median follow-up. Multivariate analysis revealed that older individuals, poor performance status, tumor proportion score < 1%, liver metastasis, baseline NLR ≥ 5, and ΔNLR ≥ 0 independently correlated significantly with shorter progression-free and overall survival (OS). Patients with high peripheral immune status (defined as NLR <5 and ΔNLR < 0) significantly improved long-term survival (2-year OS rate of 58.3%), whereas those with low peripheral immune status (defined as NLR ≥ 5 and ΔNLR ≥ 0) had extremely poor outcomes (2-year OS rate of 5.6%). Safety profiles did not differ significantly in terms of severe adverse events and treatment-related death rates despite the patients’ peripheral immune status (P = 0.46 and 0.63, respectively). Conclusions: Our study provides real-world evidence regarding clinical prognostic factors for the efficacy of chemoimmunotherapy. The combined assessment of baseline NLR and ΔNLR could facilitate the identification of patients who are likely to achieve a durable response from chemoimmunotherapy.
出版者	Adis
収録物名	Targeted Oncology
刊行年月	2024-09-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/98102
PISSN	17762596
eISSN	1776260X
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s11523-024-01084-7
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Targeted Oncology. 2024
DC.title	Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study
DC.creator	Matsumoto, Kinnosuke
	Yamamoto, Yuji
	Shiroyama, Takayuki
	Kuge, Tomoki
	Mori, Masahide
	Tamiya, Motohiro
	Kinehara, Yuhei
	Tamiya, Akihiro
	Suzuki, Hidekazu
	Tobita, Satoshi
	Ueno, Kiyonobu
	Niki, Toshie
	Nagatomo, Izumi
	Takeda, Yoshito
	Kumanogoh, Atsushi
DC.publisher	Adis
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-09-01
DC.identifier	https://doi.org/10.1007/s11523-024-01084-7
DC.description	The version of record of this article, first published in Targeted Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s11523-024-01084-7.
DCTERMS.abstract	Background: Chemoimmunotherapy is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, data on clinical predictive factors remain scarce. Objective: We aim to identify clinical biomarkers in patients undergoing chemoimmunotherapy. Methods: This multicenter, real-world cohort study included chemonaive patients who underwent chemoimmunotherapy between December 2018 and May 2022. Multivariate analysis was used to determine associations between survival outcomes and patient background, including baseline neutrophil-to-lymphocyte ratio (NLR) and its dynamic change (ΔNLR). To further investigate the clinical significance of NLR, patients were classified based on their peripheral immune status, defined by a combination of NLR and ΔNLR. Results: The study included 280 patients with 30.1 months of median follow-up. Multivariate analysis revealed that older individuals, poor performance status, tumor proportion score < 1%, liver metastasis, baseline NLR ≥ 5, and ΔNLR ≥ 0 independently correlated significantly with shorter progression-free and overall survival (OS). Patients with high peripheral immune status (defined as NLR <5 and ΔNLR < 0) significantly improved long-term survival (2-year OS rate of 58.3%), whereas those with low peripheral immune status (defined as NLR ≥ 5 and ΔNLR ≥ 0) had extremely poor outcomes (2-year OS rate of 5.6%). Safety profiles did not differ significantly in terms of severe adverse events and treatment-related death rates despite the patients’ peripheral immune status (P = 0.46 and 0.63, respectively). Conclusions: Our study provides real-world evidence regarding clinical prognostic factors for the efficacy of chemoimmunotherapy. The combined assessment of baseline NLR and ΔNLR could facilitate the identification of patients who are likely to achieve a durable response from chemoimmunotherapy.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	98102
citation_title	Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study
citation_author	Matsumoto, Kinnosuke
	Yamamoto, Yuji
	Shiroyama, Takayuki
	Kuge, Tomoki
	Mori, Masahide
	Tamiya, Motohiro
	Kinehara, Yuhei
	Tamiya, Akihiro
	Suzuki, Hidekazu
	Tobita, Satoshi
	Ueno, Kiyonobu
	Niki, Toshie
	Nagatomo, Izumi
	Takeda, Yoshito
	Kumanogoh, Atsushi
citation_publisher	Adis
citation_language	英語
citation_date	2024-09-01
citation_journal_title	Targeted Oncology
citation_doi	https://doi.org/10.1007/s11523-024-01084-7
citation_public_url	https://hdl.handle.net/11094/98102

Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study

閲覧可能ファイル

論文情報

論文詳細を表示